The National Institute of Health recently provided $2.6 million of funding for a collaboration between Interthyr Corporation and Ohio University that could result in a new drug to treat pancreatic cancer and other autoimmune diseases. For the project, Interthyr Corporation--whose CEO Leonard Kohn recently retired from the faculty of Ohio University's College of Osteopathic Medicine--will work alongside an OU research team led by Dr. Goetz.

Dr. Goetz is a professor of chemical and biomecular engineering and an NQPI member. For more information about his collaboration with Interthyr Corporation, read this article from the Ohio University Office of Research Communications.